UBS rates FXJ as a buy with a target of $0.75 - reasons given are cost savings target and the proposed pay wallhttp://www.eurekareport.com.au/broker-alerts/all%20companies
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025